Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
---|---|---|---|---|
Park S et al. | 2015 | animal, rat/Sprague Dawley, whole body | magnetic field, 50/60 Hz | 200 µT |
Sun W et al. | 2010 | intact cell/cell culture, isolated villi tissue | magnetic field, low frequency, 50/60 Hz | 0.2–0.4 mT |
Grassi C et al. | 2004 | intact cell/cell culture, human neuroblastoma cell line (IMR 32) and rat pituitary (GH3) cell line | magnetic field, low frequency, 50/60 Hz, co-exposure | 200–500 µT |
Feng B et al. | 2016 | intact cell/cell culture, human amniotic cells | magnetic field, 50/60 Hz | 0.2–2 mT |
Koh EK et al. | 2008 | intact cell/cell culture, different human prostate carcinoma cell lines (DU145, LNCaP, PC3) | magnetic field, 50/60 Hz, power transmission line | 0.2–2.5 mT |
Blumenthal NC et al. | 1997 | intact cell/cell culture, rat tendon fibroblasts and rat bone marrow osteoprogenitor cells (Sprague-Dawley rat) | magnetic field, static magnetic field, intermediate frequency, 50/60 Hz | 0.25–0.5 mT |
Tofani S et al. | 2001 | intact cell/cell culture, WiDr (colon adenocarcinoma cells), MCF-7 (breast adenocarcinoma cells), MRC-5 (embryonal lung cells), animal, mouse/CD-1 nu-nu (nude), whole body | magnetic field, static magnetic field, low frequency, 50/60 Hz, DC | 300 µT–2.5 mT |
Jia HL et al. | 2014 | intact cell/cell culture, PC-12 cells (pheochromocytoma cell line from rat adrenal gland) | magnetic field, 50/60 Hz, co-exposure | 400 µT |
Qiu L et al. | 2016 | intact cell/cell culture, human amniotic (FL) cells | magnetic field, 50/60 Hz | 0.4 mT |
Santini MT et al. | 2003 | intact cell/cell culture, human osteosarcoma cell lines (MG-63 and Saos-2) | magnetic field, 50/60 Hz | 500 µT |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.